Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) Gross Margin: 2014-2025

Historic Gross Margin for Aytu Biopharma (AYTU) over the last 11 years, with Sep 2025 value amounting to 66.14%.

  • Aytu Biopharma's Gross Margin fell 617.00% to 66.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 67.56%, marking a year-over-year decrease of 751.00%. This contributed to the annual value of 69.04% for FY2025, which is 621.00% down from last year.
  • As of Q3 2025, Aytu Biopharma's Gross Margin stood at 66.14%, which was down 2.37% from 67.75% recorded in Q2 2025.
  • Over the past 5 years, Aytu Biopharma's Gross Margin peaked at 77.89% during Q4 2023, and registered a low of -3.35% during Q1 2021.
  • Its 3-year average for Gross Margin is 69.02%, with a median of 69.40% in 2025.
  • In the last 5 years, Aytu Biopharma's Gross Margin plummeted by 7,885bps in 2021 and then surged by 5,578bps in 2022.
  • Quarterly analysis of 5 years shows Aytu Biopharma's Gross Margin stood at 53.18% in 2021, then spiked by 1,262bps to 65.81% in 2022, then skyrocketed by 1,209bps to 77.89% in 2023, then tumbled by 1,140bps to 66.49% in 2024, then slumped by 617bps to 66.14% in 2025.
  • Its Gross Margin stands at 66.14% for Q3 2025, versus 67.75% for Q2 2025 and 69.40% for Q1 2025.